Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Which ventricular tachycardia is dangerous?

S Gursoy1, R Brugada, J Brugada

  • 1Cardiovascular Center, OLV Hospital, Aalst, Belgium.

Clinical Cardiology
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IMPACT OF RADIOFREQUENCY CATHETER ABLATION ON HEALTH-RELATED QUALITY OF LIFE ASSESSED BY THE SF-36 QUESTIONNAIRE IN PATIENTS WITH PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA.

Georgian medical news·2018
Same author

INFLUENCE OF CATHETER ABLATION OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA ON PATIENTS' ANXIETY.

Georgian medical news·2018
Same author

Clinical News.

British journal of hospital medicine (London, England : 2005)·2018
Same author

[Hypothermia-induced ECG changes: characteristic, but not specific].

Medizinische Klinik, Intensivmedizin und Notfallmedizin·2017
Same author

ANXIETY LEVELS IN PATIENTS WITH PAROXY-SMAL SUPRAVENTRICULAR TACHYCARDIA IN RELATION WITH THE PATIENT DEMOGRAPHICS, TYPE OF SUPRAVENTRICULAR TACHYCARDIA AND THEIR PERSONALITY TYPE.

Georgian medical news·2017
Same author

Differential atrial performance at rest and exercise in athletes: Potential trigger for developing atrial dysfunction?

Scandinavian journal of medicine & science in sports·2016

Treating ventricular arrhythmias is challenging. Patients with sustained ventricular tachycardia and severe symptoms like syncope or heart failure may need an implantable defibrillator; others benefit from medical therapy.

Area of Science:

  • Cardiology
  • Electrophysiology

Background:

  • Ventricular arrhythmias pose significant challenges in cardiac patient management.
  • Clinical history provides crucial data for assessing arrhythmia severity and prognosis.

Purpose of the Study:

  • To outline treatment strategies for ventricular arrhythmias based on patient presentation and risk factors.
  • To identify criteria for implantable defibrillator candidacy versus medical therapy.

Main Methods:

  • Review of clinical history elements impacting survival.
  • Assessment of left ventricular function and hemodynamic effects of ventricular tachycardia.
  • Application of NYHA classification for dyspnea severity.

Main Results:

  • Left ventricular function and hemodynamic impact are key determinants of survival in ventricular tachycardia.

Related Experiment Videos

  • Patients experiencing syncope, cardiac arrest, or severe dyspnea (NYHA class III-IV) are candidates for defibrillators.
  • Otherwise, medical therapy is the recommended approach for ventricular tachycardia management.

    • Conclusions:

    • Risk stratification using clinical history, ventricular function, and hemodynamic status is essential for ventricular arrhythmia treatment.
    • Implantable defibrillators are indicated for high-risk patients with sustained ventricular tachycardia.
    • Medical therapy remains a primary option for less severe cases of ventricular tachycardia.